Stimulation of fibroblast chemotaxis by human recombinant tumor necrosis factor alpha (TNF-alpha) and a synthetic TNF-alpha 31-68 peptide by unknown
Macrophages are a major source offibrogenic factors that
promote healing ofdamaged connective tissue resulting
from injury inflicted by various types of trauma, inflamma-
tion, and immune reactions. An early event in fibrogenesis
is the recruitment of neighboring fibroblasts to the site of
injury to synthesize and remodel new connective tissue ma-
trix (1). Several macrophage-derived fibroblast chemoattrac-
tants (e.g., TGF-)l3, fibronectin, and platelet-derived growth
factor) have been previously described that could direct this
fibroblast recruitment (2-4). In the present study, it has been
demonstrated that an additional macrophage product, TNF-a,
possesses fibroblast chemotactic activity. Structure-function
studies using synthetic TNF-ci peptides indicate that fibro-
blast chemotactic activity may be mediated through amino
acid sequences residing between residues 31 and 68.
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Summary
Macrophages are a major source of fibrogenic factors that promote healing of injured tissue.
The recruitment of fibroblasts to sites of tissue injury is a prerequisite for optimal repair of tissue
damage. In the present study, human recombinant tumor necrosis factor a (hrTNF-a), a major
macrophage-derived cytokine, was demonstrated to be a potent fibroblastchemoattractant, inducing
migration at picomolar concentrations. Anti-hrTNF-oi monoclonal antibody neutralized most
of the fibroblast chemotactic activity generated during short-term culture of human peripheral
blood monocytes stimulated with bacterial lipopolysaccharide, suggesting that TNF-ci is a major
monocyte-derived fibroblast chemoattractant. The portion of the human TNF-ot molecule
responsible for its chemotactic stimulation of fibroblasts appears to reside in residues 31-68. This
region is highly conserved between TNF-tx and lymphotoxin. This peptide is not only itself
chemotactic but is also able to block the chemotactic response of fibroblasts to hrTNF-a and
vice versa, suggesting that they each mediate fibroblast migration through similar mechanisms.
These data further underscore the potential importance of TNF-ci in modulating a variety of
fibroblast functions, including chemoacxis and synthesis ofcollagen, glycosaminoglycans, interleukin
1a (IL1a) and -a, human histocompatibility leukocyte antigen A and B antigens, collagenase,
prostaglandin EZ, and ID6.
Fibroblast Chemotaxis.
￿
Fibroblasts grown in monolayer cultures
from infant foreskin explants were used as indicator cells in chemo-
taxis studies. Fibroblasts were cultured in maintenance medium
(Eagle's MEM supplemented with 9% FCS, nonessential amino
acids, 50 Pg/ml ascorbic acid, 100 U/ml penicillin, 100 Etg/ml strep-
1749
tomycin, and 5 14g/ml amphotericin B). Fibroblast migration was
quantitated as previously described using blind-well Boyden-type
chambers equipped with gelatin-treatedpolycarbonate filters (8-Am
pore size; Nucleopore Corp., Pleasanton, CA) (5).
Chemoattractants. Human recombinant TNF-tx (HrTNF-a)'
was purchased from Genzyme Corp. (Boston, MA) and had a specific
activity of 2 x 10' neutralizing U/mg of protein. Porcine platelet-
derived TGF-#1 was purchased from R & D Systems (Minneapolis,
MN). FMLP was purchased from Sigma Chemical Co. (St. Louis,
MO).
AntiTNF-a and Anti-TCF-01 Antibodies.
￿
Specific rabbit anti-
porcine TGF-/31 IgG was purchased from R & D Systems. Rabbit
anti-hrTNFct antiserum was purchased from Genzyme Corp. Anti-
hrTNF-cY mAb was a generous gift from Genentech Corp. (San
Francisco, CA). Aliquots of these antibody preparations diluted
in PBS (Gibco Laboratories, Grand Island, NY) or PBS alone were
incubated with TGF-,Q1, hrTNF-a, or supernatants from mono-
cytes cultured with LPS (described below) at 4°C for 12 h with
continuous mixing on a rocker platform.
Synthesis ofHuman TNFcr Peptides.
￿
Peptides ofvarious lengths
representing the COOH-terminal 148 residues of the deduced
human TNF-a sequence (6) were synthesized by the solid-phase
'Abbreviations used in this paper hrTNF-a, human recombinant TNF-a;
MNL, mononuclear leukocytes; OIF, oil immersion field; PDGF, platelet-
derived growth factor.
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1749-1756method of Merrifield(7) with the aid ofan automated peptide syn-
thesizer (990; Beckman Instruments, Inc., Palo Alto, CA). The
peptides were purified by gel filtration and reverse-phase HPLC (8).
Amino acid composition of each peptide was confirmed by use of
an automatic aminoacid analyzer (121 MB; Beckman Instruments,
Inc.) (9).
Isolation and Culture ofPeripheral Blood Monocytes.
￿
Blood taken
by venipuncture from healthy human volunteers was collected in
heparinized syringes and centrifuged on Ficoll-Hypaque cushions
to obtain a population of mononuclear leukocytes (MNL), as pre-
viously described (10) . After washing in RPMI 1640 containing
fresh L-glutamine, penicillin (100 U/ML), and streptomycin (100
pg/ml) (Gibco Laboratories), a monocyte-enriched population was
obtained by subjecting the MNL to centrifugal elutriation, as pre-
viously described (11). To obtain highly purified monocyte popula-
tionsofcells, elutriatedMNL were labeled with M02-R01 (mono-
cyte-specific PE conjugate) and KC56-FITC (T 200 Ag) (pan
leukocyte marker) (Coulter Cyto-Stat; Coulter Immunology, Hi-
aleah, FL) and sorted as previously described (12) .
To generate supernatants containing products from activated
monocytes, elutriated monocytes (4 x 106 cells) and sorted mono-
cytes (6 x 101) were placed in separate wells of 24-well 3424 Mark
II Cluster Dishes (Costar, Cambridge, MA), each in 1 ml ofserum-
free RPMI 1640 containing streptomycin (100 l g/ml), penicillin
(100 U/ml), fresh L-glutamine (300 pg/ml), and 100 ng/ml LPS
W from Escherichia coli 055 :BB (Difco Laboratories, Inc., Detroit,
MI). Monocytes were cultured for 48 h at 37°C in an incubator
with a humidified atmosphere containing 5% CO2. Culture su-
pernatants were harvested, clarified by centrifugation, and stored
at -70°C for up to 4 d before study.
Results
Chemotaxis ofFibroblasts to hrTNF-a.
￿
On a total of three
occasions when wide ranges of concentrations of hrTNF-a
were studied, maximal migration of fibroblasts was consis-
tently induced by concentrations of hrTNF-a ranging from
50 to 900 pg/ml (1.39-25 pM). A representative dose-response
curve is presented in Fig. 1. The response curve was always
dose dependent and bell shaped. Similar bell-shaped response
curves have been previously reported with other fibroblast
chemoattractants (2, 3) . To assess whether TNF-a was in-
ducing migration of fibroblasts by acting as a chemokinetic
or chemotactic agent, a Zigmond-Hirsch checkerboard anal-
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Figure 1 .
￿
HrTNF-awas added to the lowercompartment ofchemotaxis
chambers at the concentrations indicated, and migration offibroblasts was
quantitated.
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ysis was performed. TNF-a caused migration of fibroblasts
only when it was present in excess in the lower compart-
ment of the chemotaxis chambers, indicating that it acts as
a chemotactic agent (Table 1). Similar results were obtained
when this experiment was repeated (data not shown).
Inhibition ofTNF-a-induced Chemotaxis byAntiTNF-a An-
tibodies. To assess the effect of anti-hrTNF-a antibodies on
the ability of hrTNF-a to induce fibroblast chemotaxis,
hrTNF-a or TGF-01 (an unrelated chemotactic cytokine) were
incubated for 12 h at 4°C with polyclonal rabbit anti-hrTNF-a
or anti TGF-01 antibodies, or with anti-hrTNF-ca mAb. There
was marked inhibition of the chemotactic response of fibro-
blasts to TNF-a when it was preincubated with polyclonal
anti-hrTNF-a antiserum or with anti-hrTNF-a mAb, but
no inhibition ofchemotaxis was observed when TNF-ca was
treated with anti TGF-(31 IgG (Table 2) . The anti-hrTNF-a
antiserum and anti-hrTNF-ca mAb did not reduce the chemo-
tactic response of fibroblasts to TGF-(31, indicating that their
effect was not through a general suppression ofthe chemotactic
responsiveness of fibroblasts (Table 2) .
Chemotaxis ofFibroblasts to FMLP.
￿
It has been suggested
that the chemotactic activity for neutrophils and monocytes
reported with some preparations of hrTNF-a derived from
E. coli might be due to small amounts of contaminating
N-formylated methionyl peptides or N-formylated methionyl-
hrTNF-a (13). Therefore, it was of interest to explore the
possible role of N-formylated compounds in mediating the
fibroblast chemotactic response to hrTNF-ac. FMLP is a pro-
totype of bacteria-derived N-formylmethionyl chemotactic
peptides that have been studied extensively in neutrophils and
monocytes (14, 15). Therefore, the ability of FMLP to in-
duced fibroblast migration was assessed. In a total of three
dose-response experiments performed, FMLP induced fibro-
blast migration at 10 fM to 10 pM. A representative dose-
Table I.
￿
Effect of Varying Concentration Gradients of
hrTNF-a on Fibroblast Migration
Different concentrations of hrTNF-a were added to the upper and/or
lower compartments of chemotaxis chambers, and the number of fibro-
blasts migrating to the lower surface of each filter was quantitated. Each
value represents the mean of four replicates ± SEM of fibroblasts per
20 oil immersion field (OIF).
The number of fibroblasts migrating when hrTNF-ai was present in
a given chernotaxis chamber at the same concentration in the upper and
lower compartments.
hrTNF-ac
concentration
in upper
compartment 14.4 pin
hrTNF-at
lower
72. pm
contentration in
compartment
3.6 pm 1 .8 pin 0 pin
pm
14.4 8±1 * 7±1 7±1 8±2 8*_ 1
7.2 17±3 8±1" 7±1 7±1 9±2
3.6 52±6 32±4 12±3'10±1 15±2
1 .8 44±2 32±5 34±4 11±1* 8±1
0 72±11 45±2 36±5 15±2 13±2'' For exp. 1, aliquots of hrTNF-ai (1 ng in 100 ul PBS) and TGF-S1 (80 pg in 100 ttl PBS) were separately incubated at 4°C overnight with
10 P.l rabbit anti-hrTNF-a antiserum plus 15 ILI PBS, 25 ttl rabbit anti-TGF-01 IgG (5 ftg), or 25 A1 PBS. The samples were then brought to
a volume of 2 ml in serum-free maintenance medium and assayed for fibroblast chemotactic activity. For Exp. 2, aliquots of hrTNF-a (1 ng in
100 Ftl PBS and TGF-01 [200 pg in 100 ml PBSI) were separately incubatedat 4°C overnight with 25 til PBS or anti-hrTNF-a monoclonal IgGl
(20 jig/25 jAl PBS). The sampleswere then broughtup to avalueof 2 ml in serum-free maintence medium andassayedfor fibroblast chemotactic activity.
t Chemotactic values obtained with treatment of each chemoattractant with anti-hrTNF-a or anti-TGF-01 were compared with values obtained
after similar treatment with PBS and analyzed by student's t test.
5 Fibroblasts per 20 OIF.
response curve is plotted in Fig. 2. Zigmond-Hirsch checker-
board analysis indicated that this migration was predominantly
chemotactic in nature since most migration occurred when
FMLP was present in excess in the lower compartment of
the Chmotaxis chambers (Table 3). Similar results were ob-
served when this experiment was repeated (data not shown).
On neutrophils, there appears to be a single class of receptor
that recognizes most formylated methionyl peptides, and
FMLP can compete for binding of synthetic and bacteria-
derived chemotactic formylated methionyl peptides to this
class ofreceptor (14, 15). Ifthere were formylated methionyl
peptides in the hrTNF-a preparation, these neutrophil-related
data would imply that it should be possible to block their
chemotactic effect on fibroblasts by allowing FMLP to be
present in the upper cell compartment of the Chmotaxis
chambers when the Chmotaxis assay is performed. When
FMLP was added to the upper compartment of Chmotaxis
chambers containing fibroblasts, it could not block the migra-
tion to hrTNF-a, but it did block the response to FMLP
(Table 4). These findings, although indirect, suggest that the
chemotactic response offibroblasts to hrTNF-ca is not medi-
ated through a receptor recognizedby or a mechanism related
to FMLP.
Chemotaxis ofFbbmblasts to Synthetic TNF-a 31-68.
￿
In an
effort to localize the region of the TNF-a molecule involved
in the fibroblastchemotactic response, synthetic peptides were
made representing all but the first nine amino acids ofhuman
TNF-a, and tested for their ability to induce fibroblastmigra-
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tion (Fig. 3). Peptides were repeatedly tested over a wide con-
centration rangefor their ability to induce fibroblast migra-
tion. Only one peptide, TNF-a 31-68, induced fibroblast
migration (Fig. 4). The response curve, like that ofhrTNF-a,
was bell shaped (Fig. 4). Zigmond-Hirsch checkerboard anal-
ysis indicated that this active peptide induced mostly chemo-
tactic migration of fibroblasts (Table 5). A small amount of
chemokinetic activity was repeatedly observed at intermediate
concentrations of the peptide (Table 5). To assess the rela-
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Figure 2.
￿
Astock solution of FMLP (1 mM) was prepared by slowly
adding NaHC03 to a suspension of FMLP in waterwith frequent vor-
tex]ng until thesolution was clear. Various concentrations of FMLP pre-
paredfrom this stocksolution weretested fortheir abilityto induce fibroblast
migration.
Table 2 . Inhibition of hrTNF-a-induced Chemotaxis by Anti-hrTNF-a Antibodies
Exp. Condition' Chemotactic activity p valuet
1 hrTNF-a (29.4 pM) + PBS 33 ± 45
hrTNF-a (29.4 pM) + anti-hrTNF-ac 4 ± 1 <0.0025
hrTNF-a (29.4 pM) + anti-TGF-(31 42 ± 6 NS
TGF-01 (1.6 pM) + PBS 35 ±5
TGF-/31 (1.6 pM) + anti-hrTNF-a 39 ± 4 NS
TGF-01 (1.6 pM) + anti-TGF-fl1 10 t 2 <0.0025
PBS 9 ±1
2 hrTNF-a (29.4 pM) + PBS 103 ± 15
hrTNF-a (29.4 pM) + anti-hrTNF-ca mAb 9 ± 2 <0.0001
TGF-(31 (4 pM) + PBS 76 ± 10
TGF-01 (4 pM) + anti-hrTNF-a mAb 77 ± 13 NS
PBS 12 ± 1Table 3.
￿
Effect of Varying Concentration Gradient ofFMLP
on Fibroblast Migration
FMLP concentration in lower
compartment
FMLP concentration
in upper compartment
￿
5 fM
￿
1 fM
￿
0.5 fM
￿
0 fM
fm
FMLP was added to upper and lower compartments of modified blind-
well chemotaxis chambers at theconcentrations indicated, andfibroblast
migration was quantitated. Each value represents themean offour repli-
cates t SEM.
* The number offibroblasts migratingwhen FMLP waspresentin agiven
chemotaxis chamber at the same concentration in theupper and lower
compartments.
tionship of thechemotactic response of fibroblasts to TNF-a
31-68 and hrTNF-a, we repeatedly performed experiments
in which the fibroblasts in the upper cell compartment of
the chemotaxis chambers were suspended in either media,
hrTNF-a, or TNF-a 31-68, and compared the migration
of variously treated fibroblasts to hrTNF-a, TNF-a 31-68,
TGF-01, andmedia. Results of a typical experiment areshown
in Table 6. HfNF-a and TNF-a 31-68 were equallyeffec-
tive in blocking the migration of fibroblasts to each other,
butneitherblocked theresponse to TGF-f1(Table 6). These
data suggest that hrTNF-aandTNF-a31-68 induce fibroblast
migration through either acommon receptor or mechanism.
Neutralization by AntiTNRa mAb ofFibroblast Chemotactic
Actitriry in Supernatantsfrom Cultures ofHumanMonocytesStimu-
lated by LPS. Since monocytes/macrophages are potential
sourcesof several fibroblast chemoattractants (e.g., TGFO-1,
fibronectin, leukotriene B4, platelet-derived growth factor
[PDGF]), it was important to determine therelative portion
of fibroblasts chemotactic activity in cultures of stimulated
human peripheral blood monocytes attributable to TNF-a.
10-36$
￿
Asp Lys Pro Val Ala His Val Val Ala Asn Pro
Gln Trp Leu Asn Arg Arg Ala Asn Ala Leu
31-68
￿
Arg Arg Ala Asn Ala Leu Leu Ala Asn Gly Val
Leu Val Val Pro Ser Glu Gly Leu Tyr Leu Ile
Lys Gly Gln Gly
101-135
￿
Cys Gln Arg Glu Thr Pro Glu Gly Ala Glu Ala
Ile Tyr Leu Gly Gly Val Phe Gln Leu Glu Lys
Glu
136-157
￿
Ile Asn Arg Pro Asp Tyr Leu Asp
Gly Ile Ile Ala Leu
1752
Gln Ala Glu
Glu Leu Arg
Tyr Ser Gln
Pro Ser Thr His Val Leu Leu Thr His Thr Ile Ser Arg Ile Ala Val 69-100 Cys
Ser Tyr Gln Thr Cys Val Asn Leu Leu Ser Ala Ile Cys Ser Pro
Phe Ala[Glu Ser Gly Gln Val Tyr
Tumor Necrosis Factor a-induced Fibroblast Chemotaxis
Table 4.
￿
Effect of incubation of Fibroblasts with FMLP on the
Chemotactic Response to hrTNF-a
Condition*
￿
Chemotactic activity
￿
p value*
Fibroblasts incubated with media
hrTNF-a (29.4 pM)
￿
37 ± 6S
FMLP (10 fM)
￿
45 ± 6
Media
￿
5 ± 1
Fibroblasts incubated with FMLP (100 pM)
hrTNF-a (29.4 pM)
￿
36 ± 4
￿
NS
FMLP (10 fM)
￿
7 ± 1
￿
<0.0004
Media
￿
3 ± 1
￿
NS
* Fibroblasts were suspendedin complete serum-free maintenance media
with or without 100 pM FMLP and added to the upper compartment
ofchemotaxis chambers. Migration offibroblasts to FMLP and complete
serum-free mediawas then measured. Values represent themean t SEM
of quadruplicate values.
tThe chemotactic activities obtained when lower compartments of
chemotaxis chambers contained hrfNF-a, FMLP,or media, andtheupper
compartment contained fibroblasts suspended in FMLP (100 pM) were
each compared by the two-sample student's t test with thevalues deter-
mined in chambers containing fibroblasts suspended in media.
S Fibroblasts per 20 OIF.
To assess this, peripheral blood monocytes purified by cen-
trifugal elutriation or centrifugal elutriation and FRCS were
stimulated for 24-48 h by LPS, and the harvested superna-
tants, aftertreatment with anti TNF-amAb or PBS as acon-
trol, were tested at various dilutionsfor fibroblast chemotactic
activity. Supernatant from cultures of elutriated monocytes
stimulated with LPS elicited maximal chemotactic response
offibroblasts at a 1:80 dilution (Fig. 5 A). The chemotactic
activity at this and other dilutions of the supernatant was
almost totally neutralized by anti-hrTNF-a mAb (Fig. 5 A).
Supernatants from elutriated and sorted monocytes stimu-
lated with LPS induced fibroblast migration at 1:20, 1:40,
and 1:80 dilutions (Fig. 5 B). Anti-hrTNF-a mAb neutral-
ized most of the fibroblast chemotactic activity in the super-
natant at these dilutions (Fig. 5 B) . These data suggest that
Gly Gln Ile
Asp Asn Gln
Val Leu Phe
Lys Pro Trp Tyr Glu
Gly Asp Arg Leu Ser
Pro
Ala
Phe
Figure 3. Peptides representing the deduced
human TNF-asequence were synthesized by the
solid-phase method of Merrifield (7) on an auto-
matedpeptidesynthesizer (990; Beckman Instru-
ments, Inc.) (8). (*)This peptidewas synthesized
without residues 1-9. It has been previously
demonstrated that NHZ-terminal residues arenot
essential for TNF-a activity (19).
5 24±3*
14 t1 13 t2 9±1
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￿
Synthetic TNF-a 31-68 was added to the lower compart-
ment ofchernotaxis chambers at theconcentrations indicated, andmigra-
tion of fibroblasts was quantitated.
TNF-a is the major fibroblast chemoattractant produced by
peripheral blood monocytes under these experimental con-
ditions.
Discussion
HrTNF-a is a potent chemotactic agent for fibroblasts in
vitro inducing their migration at picomolar concentrations.
The TNF-at fibroblast chemotactic dose-response curve is bell
shaped. This type dose-response curve has been previously
observed with several different fibroblast chemotactic agents
and with FMLP in this present study (2-4). A synthetic pep-
tide representing the TNF-ca amino acid sequence 31-68 also
induced chemotaxis of fibroblasts. TNF-a 31-68 was much
less potent than hrTNF-a in inducing chemotaxis. A similar
reduction of potency has been reported with synthetic pep-
tides of growth hormone and of human IL10 (16-18). The
reduced potency ofTNF-a 31-68 relative to hrTNF-(x is likely
1753
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Table 5.
￿
Effect of Varying Concentration Gradients of TNF-a Peptide 31-68 on Fibroblast Migration
alues
" Fibroblasts were suspendedin complete serum-free maintenance media
with or without hrTNF-a (29.4 pM) or TNF-a 31-68 (164 nM) and
addedto theuppercompartment ofchemotaxis chambers. Migrationof
fibroblasts to hrTNF-a, TNF-a 31-68, TGF-S1, or mediawasthen quan-
titated. Values represent the mean t SEM of quadruplicate values.
t The chemotactic activities obtained when the lower compartment of
chemotaxis chambers contained each chemoattractant or media and the
uppercompartment of the chambers contained fibroblasts suspended in
hrTNF-aor TNF-a 31-68 were each compared by the two-sample stu-
dent's t test with thevalues generated in chambers containing fibroblasts
suspended in media.
S Fibroblasts per 20 OIF.
Different concentrations of synthetic TNF-ci 31-68 were added to theupper and/or lower compartments of chemotaxis chambers, and the number
of fibroblasts miograting to the lower surface of each filter was quantitated. Each value represents the mean of four replicates ± SEM of fibroblasts
per 20 01F.
" The number of fibroblasts migrating when the peptide was present in a given chemotaxis chamber at the same concentration in the upper and
lower compartments.
Fibroblasts suspended in hrTNF-a (29.4 pM)
hrTNF-a (29.4 pM) 12 ± 3 <0.0001
TNF-a 31-68 (164 nM) 11 ± 3 <0.0001
TGF-S (1 .6 pM) 123 ± 10 NS
Media 17 ± 3 NS
Fibroblasts suspended in TNF-a 31-68 (164 nM)
hrTNF-a (29.4 pM) 16 f 2 <0.0001
TNF-a 31-68 (164 nM) 17 ± 3 <0.0001
TGF-01 (1.6 pM) 135 t 16 NS
Media 12 ± 1 NS
Table 6. Effect of Incubation of
or TNF-a 31-68
Condition"
Fibroblasts
Chemotactic
with hrTNF-a
activity p
Fibroblasts suspended with media
hrTNF-ac (29.4 pM) 118 ± 105
TNF-a 31-68 (164 nM) 144 ± 5
TGF-R (1 .6 pM) 137 ± 10
Media 16 ± 1
TNF-a peptide 31-68 concentration
in upper compartment 329 nM
TNFa peptide 31-68
164 nM
concentration
41 nM
in lower compartment
21 nM 0 nM
nM
329 8 ± 1" 12±2 9±1 10±1 16f3
164 43 ± 3 22±4. 16±3 11±1 14±2
41 57 ± 6 47±5 26±4. 28±5 31±2
21 67 ± 2 46±2 49±7 9±1. 20±6
0 86 ± 13 73±4 57±3 31±4 17±3'Figure 5 .
￿
(A) Monocytes were purified by centrifugal elutriation (>85%
pure as assessed by FACS analysis) . (B) Monocytes from a different elutri-
ator run were purified further by sorting (by>98% monocytes as assessed
by FACS anlaysis) . Elutriated and sorted monocytes were cultured for 48 h
with LPS as described in Materials and Methods. Aliquots of supernatants
(100 ul) were incubated overnight with 5 Pl PBS (as a control) or with
5 jil (4I`g) antiTNF-ca,mAb (Genentech) at 4°C . The supernatants were
then tested at dilutions indicated for their ability to induce fibroblast migra-
tion. Results inA and B are from two different fibroblast chemotaxis as-
says . (=) PBS-treated supernatants; (®) antiTNF-a mAb-treated
supernatant.
due to its small size and lack of other amino acid sequences
necessary for binding to TNF-a receptors or for conferring
secondary, tertiary, and quaternary structural features for op-
timal interaction with fibroblasts .
The finding that a synthetic peptide ofTNF-a composed
of residues 31-68 has a biologic activity of the parentTNF-a
molecule is of special interest since a particularly conserved
region ofhuman TNF-a occurs in amino acids 35-66 . This
region shares 50% amino acid homology with human lym-
photoxin (6) . X-ray crystallographic analyses indicate that
TNF-a forms a trimer with residues near the COON and
NH2 termini, being located at the base of the trimer and
likely involved in receptor binding (19) . A pocket lined by
highly conserved (betweenhuman TNF-a and lymphotoxin)
sequences 11-13, 37-42, 49-57, and 155-157 may be criti-
cally involved in binding ofTNF-a and lymphotoxin to its
receptor (19) . We have not yet assessed the ability ofTNF-a
31-68 or the remaining TNF-a peptides used in this study
to compete with hrTNF-ci binding to its receptor.
Although FMLP was also found to be a potent fibroblast
chemoattractant in the present study, several different lines
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of evidence suggest that trace or low concentrations of
N-formylmethionyl peptides are not involved in the chemo-
tactic response of fibroblasts to the hrTNF-a preparations
tested . First, mAb to hrTNF-ci selectively blocked the chemo-
tactic response offibroblasts to hrTNF-a but not to TGF-ail .
This argues against trace contaminants ofN-formylmethionyl
peptides in the hrTNF-a preparations being responsible for
the fibroblast chemotactic response . Second, a synthetic pep-
tide consisting ofTFN-a residues 31-68 is itselfchemotactic
for fibroblasts and can selectively inhibit the migration of
fibroblasts to hrTNF-a and vice versa, suggesting both the
peptide and hrTNF-a induce fibroblast chemotaxis through
a similar mechanism(s) . Finally, FMLP, a prototype peptide
for N-formylmethionyl chemoattractants that should block
the chemotactic response offibroblasts to N-formylmethionyl
peptides, does not block the chemotactic response of fibro-
blasts to hrTNF-a .
Other fibroblast functions have been reported to be affected
byTNF-a in vitro, including stimulation ofgrowth and syn-
thesis of collagenase, hyaluronic acid, prostaglandin E2 , and
11,6 (20-23) . TNF inhibits collagen gene transcription and
collagen synthesis by fibroblasts (24) . Synthesis of IIAa
and -10, and HLA-A,B mRNAs, are increased by TNF-ci,
as is surface expression ofHLA A,B antigens by fibroblasts
(25, 26) . Studies are being performed to assess the effect of
the synthetic TNF-a peptides used in this study on these
fibroblast functions as well as their ability to lyseL cell targets .
Under certain culture conditions, monocytes/macrophages
have been shown to produce several fibroblast chemoattrac-
tants (i.e., TGF-01, fibronectin, PDGF, and LTB4) . Our data
suggest that TNF-a is the major biologically active fibro-
blast chemoattractant produced during short-term culture of
peripheral blood monocytes stimulatedbyLPS. The fact that
most of the fibroblast chemotactic activity produced by LPS-
stimulated monocytes in short-term culture is TNF-a may
be due to the following. (a) TGF-91 is secreted by mono-
cytes/macrophages as a latent molecule bound to an acid-labile
binding protein that blocks its biologic activity (27, 28) . (b)
Fibronectin is synthesized by macrophages in long-term cul-
ture (4-10 d) and not during short-term culture (29) . (c) Most
(up to 80%) ofPDGF secreted by macrophages is bound to
acid labile proteins (mostly a2-macroglobulin) and, like
TGF-(31, require acidification for expression of biologic and
receptor binding activity (30) . (d) Macrophages do not syn-
thesize LTB4 in response to LPS stimulation (31) .
TNF-a is synthesized by a variety of different macrophages,
including those of pulmonary, hepatic, bone marrow, and
peritoneal origins, and perhaps byT lymphocytes, mast cells,
smooth muscle cells, and NK cells under certain circumstances
(see reference 32 for review) . Macrophages produce TNF-ci
after exposure to many different stimuli, including LPS, some
Gram-positive organisms, lysates o£certain parasites, and Sendai
and influenza viruses (see reference 32 for review) . When
hrTNF-a is daily injected subcutaneously into laboratory
animals, it induces an acute inflammatory response that is
followed by chronic inflammation, accumulation of fibroblasts,
and fibrosis (33) . This present study suggests that TNF-a
is a major monocyte/macrophage-derived product that mayfunction to direct therecruitment of fibroblasts, as do other
growth factors andproducts from activatedmacrophages, and
maybe critically involved in thefibrogenic response that typi-
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